Developmental toxic potential of di-n-propyl phthalate administered orally to rats

Anne-Marie Saillenfait1, Alain-Claude Roudot, Frédéric Gallissot

  • 1Institut National de Recherche et de Sécurité, Rue du Morvan, CS 60027, 54519 Vandoeuvre Cedex, France. anne-marie.saillenfait@inrs.fr

Insights

Di-n-propyl phthalate (DnPP) exposure in pregnant rats reduced maternal weight gain and fetal body weight, and decreased male anogenital distance. No teratogenic effects were observed, establishing a NOAEL of 0.5 g/kg/day for developmental toxicity.

Area of Science:

  • Toxicology
  • Reproductive Toxicology
  • Developmental Toxicology

Background:

  • Phthalates are common environmental contaminants.
  • Understanding the developmental toxicity of specific phthalates like di-n-propyl phthalate (DnPP) is crucial for risk assessment.

Purpose of the Study:

  • To evaluate the developmental toxic potential of di-n-propyl phthalate (DnPP) in Sprague-Dawley rats.
  • To determine dose-response relationships and establish a no-observed-adverse-effect level (NOAEL) for DnPP developmental toxicity.

Main Methods:

  • Pregnant Sprague-Dawley rats were administered DnPP via gavage at doses of 0, 0.5, 1, and 1.5 g/kg/day during gestation days 6-20.
  • Evaluated maternal toxicity, fetal body weight, anogenital distance, skeletal development, and external/visceral malformations.
  • Calculated benchmark doses for key developmental endpoints.

Main Results:

  • Maternal body weight gain was reduced at 1.5 g/kg/day.
  • Significant decreases in fetal body weight and male anogenital distance were observed at 1 and 1.5 g/kg/day.
  • Increased incidence of rudimentary ribs and delayed ossification were noted at higher doses; no teratogenicity was observed.

Conclusions:

  • DnPP exhibits developmental toxicity in rats, affecting fetal growth and male reproductive development.
  • The no-observed-adverse-effect level (NOAEL) for developmental toxicity was determined to be 0.5 g/kg/day.
  • While not teratogenic, DnPP exposure warrants careful consideration due to observed developmental effects.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...